Titre :

Efficacy and safety of sm-153-edtmp as treatment of painful bone metastasis: a large single-center study

Auteur(s) :

Kolesnikov-Gauthier, Helene [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Lemoine, Nathalie [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Tresch-Bruneel, Emmanuelle [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Olivier, Anais [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Oudoux, Aurore [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Titre de la revue :

Supportive care in cancer . official journal of the Multinational Association of Supportive Care in Cancer

Nom court de la revue :

Support. Care Cancer

Numéro :

26

Pagination :

751-758

Éditeur :

Springer Link

Date de publication :

2018-03-01

ISSN :

0941-4355

Mot(s)-clé(s) en anglais :

Radiometabolic therapy
Bone metastases
Samarium153
Pain palliative

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Purpose The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting. Methods We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP ...
Lire la suite >Purpose The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting. Methods We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question “Do you think you obtained a benefit from treatment?” Success of treatment was defined by the combination of these four parameters. Results Three hundred seventy consecutive 153Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases. Conclusion 153Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T18:17:47Z
2024-03-06T08:36:09Z